Production, concentration and deep purification of 111In radiochemicals

Filossofov, D.V.; Lebedev, N.A.; Novgorodov, A.F.; Bontchev, G. D.; Starodub, G. Ya.

doi:10.1016/s0969-8043(00)00376-6

Cited by 21 publications

(5 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The production of 111 In is well-established and can be achieved directly via nat Cd(d,xn), nat Cd(p,xn), nat Cd(α,x), nat Ag(α,xn), nat Ag( 7 Li,x), or nat Ag( 11 B,x) or indirectly by nat Rh( 12 C, x) 111 Sb → 111 Sn → 111 In, nat Sn(n,x) 111 Sn → 111 In, or nat Sn(p,x) 111 Sn → 111 In. − The most common production methods are proton or deuteron bombardment of natural or enriched cadmium targets or α bombardment of silver targets. These methods are popular because they can achieve high yields of nca 111 In while avoiding or minimizing the production of the long-lived contaminant 114m In ( t 1/2 = 1188 h).…”

Section: Indiummentioning

confidence: 99%

Radioactive Main Group and Rare Earth Metals for Imaging and Therapy

2018

View full text Add to dashboard Cite

Radiometals possess an exceptional breadth of decay properties and have been applied to medicine with great success for several decades. The majority of current clinical use involves diagnostic procedures, which use either positron-emission tomography (PET) or single-photon imaging to detect anatomic abnormalities that are difficult to visualize using conventional imaging techniques (e.g., MRI and X-ray). The potential of therapeutic radiometals has more recently been realized and relies on ionizing radiation to induce irreversible DNA damage, resulting in cell death. In both cases, radiopharmaceutical development has been largely geared toward the field of oncology; thus, selective tumor targeting is often essential for efficacious drug use. To this end, the rational design of fourcomponent radiopharmaceuticals has become popularized. This Review introduces fundamental concepts of drug design and applications, with particular emphasis on bifunctional chelators (BFCs), which ensure secure consolidation of the radiometal and targeting vector and are integral for optimal drug performance. Also presented are detailed accounts of production, chelation chemistry, and biological use of selected main group and rare earth radiometals.

show abstract

Section: Indiummentioning

confidence: 99%

Radioactive Main Group and Rare Earth Metals for Imaging and Therapy

2018

View full text Add to dashboard Cite

show abstract

“…Liquidliquid extraction and ion-exchange chromatography (IEC) are widely used for radiochemical separation of 111 In on the commercial scale. 31,32,[35][36][37][38][39] However, despite the development of robust separation and purification technology, low production yields are a major impediment in the large-scale production of 111 In required for its therapeutic use.…”

Section: Production Of Radionuclides Currently Used In Prrtmentioning

confidence: 99%

Peptide Receptor Radionuclide Therapy: An Overview

Dash

Chakraborty

Pillai³

et al. 2015

Cancer Biotherapy and Radiopharmaceuticals

102

101

View full text Add to dashboard Cite

Peptide receptor radionuclide therapy (PRRT) is a site-directed targeted therapeutic strategy that specifically uses radiolabeled peptides as biological targeting vectors designed to deliver cytotoxic levels of radiation dose to cancer cells, which overexpress specific receptors. Interest in PRRT has steadily grown because of the advantages of targeting cellular receptors in vivo with high sensitivity as well as specificity and treatment at the molecular level. Recent advances in molecular biology have not only stimulated advances in PRRT in a sustainable manner but have also pushed the field significantly forward to several unexplored possibilities. Recent decades have witnessed unprecedented endeavors for developing radiolabeled receptor-binding somatostatin analogs for the treatment of neuroendocrine tumors, which have played an important role in the evolution of PRRT and paved the way for the development of other receptor-targeting peptides. Several peptides targeting a variety of receptors have been identified, demonstrating their potential to catalyze breakthroughs in PRRT. In this review, the authors discuss several of these peptides and their analogs with regard to their applications and potential in radionuclide therapy. The advancement in the availability of combinatorial peptide libraries for peptide designing and screening provides the capability of regulating immunogenicity and chemical manipulability. Moreover, the availability of a wide range of bifunctional chelating agents opens up the scope of convenient radiolabeling. For these reasons, it would be possible to envision a future where the scope of PRRT can be tailored for patient-specific application. While PRRT lies at the interface between many disciplines, this technology is inextricably linked to the availability of the therapeutic radionuclides of required quality and activity levels and hence their production is also reviewed.

show abstract

“…111 In is usually isolated from Ag or Cd target materials by its co-precipitation with La(OH) 3 or Fe(OH) 3 . 14,6 c Then 111 In is separated from La(III) or Fe(III) by ion-exchange chromatography.…”

Section: Radiometals For Spectmentioning

confidence: 99%

Metallic radionuclides in the development of diagnostic and therapeutic radiopharmaceuticals

2011

View full text Add to dashboard Cite

Metallic radionuclides are the mainstay of both diagnostic and therapeutic radiopharmaceuticals. Therapeutic nuclear medicine is less advanced but has tremendous potential if the radionuclide is accurately targeted. Great interest exists in the field of inorganic chemistry for developing target specific radiopharmaceuticals based on radiometals for non-invasive disease detection and cancer radiotherapy. This perspective will focus on the nuclear properties of a few important radiometals and their recent applications to developing radiopharmaceuticals for imaging and therapy. Other topics for discussion will include imaging techniques, radiotherapy, analytical techniques, and radiation safety. The ultimate goal of this perspective is to introduce inorganic chemists to the field of nuclear medicine and radiopharmaceutical development, where many applications of fundamental inorganic chemistry can be found.

show abstract

Production, concentration and deep purification of 111In radiochemicals

Cited by 21 publications

References 7 publications

Radioactive Main Group and Rare Earth Metals for Imaging and Therapy

Radioactive Main Group and Rare Earth Metals for Imaging and Therapy

Peptide Receptor Radionuclide Therapy: An Overview

Metallic radionuclides in the development of diagnostic and therapeutic radiopharmaceuticals

Contact Info

Product

Resources

About